Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
Diethylstilbestrol (DES) is a synthetic nonsteroidal estrogen administered as an oral delayed-release tablet. The mechanism of action and specific indications are not currently documented in available data. This pre-launch small molecule represents a historical drug class with complex regulatory considerations.
Pre-launch status indicates this is an early-stage commercial opportunity with teams focused on regulatory clearance, launch planning, and market preparation rather than peak revenue generation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
Worked on DIETHYLSTILBESTROL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero currently linked jobs indicate this pre-launch product has minimal active hiring momentum at present. Careers would focus on launch preparation, regulatory navigation, and market access strategy within Eli Lilly's organizational structure.